Shots:

• The approval is based on P-II KEYNOTE-146/Study 111 assessing Keytruda (200mg- IV- q3w) + Lenvima (20mg- PO- qd) in 108 patients with metastatic endometrial carcinoma that is not microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) with diseases progression following prior systemic therapy and are not candidates for curative surgery or radiation
• The P-II KEYNOTE-146/Study 111 results: ORR (38.3%); CRR (10.6%); PRR (27.7%); median follow up time (18.7mos.). Under Project Orbis- Keytruda + Lenvima regimen is the first to receive simultaneous review decisions in the US- Australia and Canada
• KEYTRUDA is an anti-PD-1 therapy- act by blocking the interaction between PD-1 and its ligands- PD-L1 and PD-L2 thus activating T lymphocytes affecting both tumor and healthy cells. Lenvima is a kinase inhibitor targeting the activities of VEGF receptor including VEGFR1- VEGFR2 & VEGFR3

Click here to­ read full press release/ article

Ref: Merck | Image: Merck